Essex Savings Bank Purchases 715 Shares of Novo Nordisk A/S (NYSE:NVO)

Essex Savings Bank grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 8.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,636 shares of the company’s stock after purchasing an additional 715 shares during the period. Essex Savings Bank’s holdings in Novo Nordisk A/S were worth $829,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Sendero Wealth Management LLC grew its holdings in Novo Nordisk A/S by 35.4% during the 4th quarter. Sendero Wealth Management LLC now owns 46,413 shares of the company’s stock valued at $3,992,000 after buying an additional 12,142 shares in the last quarter. Sawyer & Company Inc purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $4,963,000. Pinnacle Bancorp Inc. increased its holdings in Novo Nordisk A/S by 29.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 1,496 shares of the company’s stock worth $129,000 after acquiring an additional 336 shares during the period. Redhawk Wealth Advisors Inc. lifted its stake in Novo Nordisk A/S by 12.7% in the 4th quarter. Redhawk Wealth Advisors Inc. now owns 21,361 shares of the company’s stock worth $1,837,000 after purchasing an additional 2,406 shares in the last quarter. Finally, Wolff Wiese Magana LLC boosted its holdings in Novo Nordisk A/S by 25,350.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 3,054 shares of the company’s stock valued at $263,000 after purchasing an additional 3,042 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $82.99 on Thursday. Novo Nordisk A/S has a fifty-two week low of $80.05 and a fifty-two week high of $148.15. The firm’s 50-day simple moving average is $99.26 and its two-hundred day simple moving average is $118.18. The stock has a market cap of $372.42 billion, a PE ratio of 26.86, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NVO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.